We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 31, 2020

SGLT2 Inhibitors vs Placebo as Add-On Therapy in Type 2 Diabetes Uncontrolled With Metformin and a DPP-4 Inhibitor

Diabetic Medicine: A Journal of the British Diabetic Association


Additional Info

Diabetic Medicine: A Journal of the British Diabetic Association
Efficacy and Safety of a Sodium-Glucose Co-Transporter-2 Inhibitor vs Placebo as an Add-On Therapy for People With Type 2 Diabetes Inadequately Treated With Metformin and a Dipeptidyl Peptidase-4 Inhibitor: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Diabet. Med. 2020 Sep 26;[EPub Ahead of Print], C De Buitléir, E O' Connor, MM Satti, J Shaw, A Liew

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading